Generated by AI
TransMedics Group, Inc. is a commercial-stage medical technology company focused on organ transplant therapy. The company develops and commercializes the Organ Care System (OCS), a platform designed to preserve, monitor, and assess donor organs outside the human body in conditions that more closely resemble a living environment. Its current portfolio supports heart, lung, and liver transplantation, helping transplant teams manage donor organs more effectively than traditional cold storage methods. TransMedics also provides related disposables and service offerings that support organ transport, preservation, and clinical workflow in the transplant process. Headquartered in Andover, Massachusetts, TransMedics Group, Inc. serves a specialized role in healthcare by addressing the needs of patients with end-stage organ failure and supporting hospitals, transplant centers, and organ recovery organizations across its markets.
Website200 Minuteman Road
Andover, MA, 01810
United States
The latest articles about TMDX.
TransMedics Group Inc. demonstrates accelerating revenue growth, improved service margins and market share gains. Read why TMDX stock is a buy.
Summary of Nov 17's posts. Generated by AI.
Summary of Aug 10's posts. Generated by AI.
Summary of Jun 21's posts. Generated by AI.
Summary of Aug 25's posts. Generated by AI.
Investors talking about TMDX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.